Trials / Terminated
TerminatedNCT05571267
Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura™ (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- IVERIC bio, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular age-related macular degeneration (AMD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avacincaptad Pegol | Zimura 2 mg, administered by intravitreal injection |
| DRUG | Avastin | Avastin 1.25 mg, administered by intravitreal injection |
| DRUG | Lucentis | Lucentis 0.5 mg, administered by intravitreal injection |
| DRUG | Eylea | Eylea 2 mg, administered by intravitreal injection |
Timeline
- Start date
- 2016-10-20
- Primary completion
- 2018-04-24
- Completion
- 2018-04-24
- First posted
- 2022-10-07
- Last updated
- 2025-03-13
- Results posted
- 2023-04-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05571267. Inclusion in this directory is not an endorsement.